Novaliq GmbH Announces Launch of a Phase 1 Study Following US and European Patent Approval of CyclASol® (Cyclosporin) Eye Drops

April 03, 2014 09:00 AM Eastern Daylight Time
HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH today announced the commencement of a Phase 1 study for CyclASol (Cyclosporin solution) following US and European patent approval of the solution for the treatment of dry eye syndrome.

"We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq's strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology. These products are intended to cover unmet needs with one major advantage being they will be preservative free"

While conventional cyclosporin formulations are emulsions, CyclASol is the first and only 0.05% clear cyclosporin solution. CyclASol is available in multi-dose and preservative free bottles for the treatment of dry eye syndrome. CyclASol has demonstrated long-term stability plus superior wettability, pharmacokinetics, and biocompatibility compared to conventional emulsions.

CyclASol was developed from Novaliq's broad range Semi Fluorinated Alkane (SFA) drug delivery platform EyeSol®, offering significant competitive advantages for multiple drug candidates within ophthalmology, primarily by enhancing the therapeutic effect of poorly soluble drugs.

"We are pleased to receive the USA & European patent and to announce the start of phase 1 CyclASol study," said Bernhard Günther, CEO of Novaliq GmbH. "These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio." In 2013 Novaliq finalized their fifth round of financing for €13.9 million ($18.1 million) with the intent to strengthen both their prescription and OTC product development programs based on SFA technology.

"We congratulate Novaliq on obtaining patent approval for CyclASol and start of their clinical trials," commented Mathias Hothum, Managing Director of Dievini Hopp BioTech Holding GmbH & Co. KG, the investment company of SAP co-founder Dietmar Hopp. "We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq's strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology. These products are intended to cover unmet needs with one major advantage being they will be preservative free," Mathias Hothum added furthermore.

About Novaliq GmbH
Novaliq is a drug delivery company whose goal is to develop innovative pharmaceutical formulations. Its patented semifluorinated alkanes (SFAs) can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops innovative ophthalmic formulations as well as solutions for organ preservation and has several product candidates with excellent market potential in various stages of development. Novaliq welcomes invitations from interested parties to enter into discussions about significant additional development or partnership opportunities.

About Dievini Hopp BioTech Holding GmbH & Co. KG
Dievini is an active investor in Life and Health Sciences companies, with a focus on innovative therapeutics and diagnostics shown to lead to novel treatment regimens allowing doctors to treat patients with life-threatening diseases more safely and efficiently than they are currently able.

Contacts
Contact USA
Scotia Vision Consultants
Michael O'Rourke, 1-813-323-1438
[email protected]
or
Contact Europe
Novaliq GmbH
Bernhard Günther, CEO, + 49 6221 502 5911
[email protected]

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.